

IMAGIN

MEDICAL


Investor Presentation

First Quarter 2020

Game Changing

Cancer Care

CSE: IME | OTCQB: IMEXF | Frankfurt & Stuttgart Symbol: DPD2



Forward-Looking Statements

These materials may contain forward-looking statements relating to the business of Imagin Medical (the “Company” or “Imagin”) including with respect to the progress, timing and completion of the Company’s research, development, and clinical trials for product candidates, the Company’s ability to manufacture, market, commercialize, partner and achieve market acceptance for product candidates, its ability to protect its intellectual property and operate its business without infringing on the intellectual property rights of others, the Company’s estimates for future performance and its estimates regarding anticipated operating losses, future revenues, capital requirements, and its needs for additional financing, and any M&A timelines. Even if the Company’s actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Company’s results or developments in the future. In some cases, you can identify forward-looking statements by words such as “could”, “should”, “may”, “expect”, “anticipates”, “believes”, “intends”, “estimates”, or similar words. These forward-looking statements are based largely on the Company’s current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements express or implied by these forward-looking statements. In particular, the Company’s expectations could be affected by, among other things, uncertainties involved in the development and manufacture of medical devices, unexpected results, unexpected regulatory actions or delays, competition in general, the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will, in fact, be realized, and no representation or warranty is given as to the completeness or accuracy of the forward-looking statements contain in these materials.

Imagin is providing the information in these materials as of this date, and we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.



Investment Highlights

Surgical Imaging Company



Dramatically improves physicians' ability to visualize cancer during Minimally Invasive Surgery (MIS)

- Initial target \$500M bladder cancer market - a “hot-button” urology issue looking for innovation
- i/Blue Imaging System is a Breakthrough Technology - risk mitigated; functional product built
- Regulatory plan in place – meetings with FDA underway
- Well protected intellectual property - 3 key patents issued, additional IP to be filed
- Strong management team - Boston based group that has done it before; world-class Scientific Advisory Board
- Active M&A driven market environment - various liquidity options

Endoscopic Market

Definitions

Minimally Invasive Surgery



Minimally Invasive Surgery

- Less muscle cut
- Performed using tiny incisions/natural orifices
- Reduced pain, smaller/no scarring, quicker recovery, shorter hospital stay, less expensive


Endoscopes

- A medical device with attached light “to look inside”
- Different medical specialties use different types of endoscopes
- Cystoscopes, laparoscopes, gastroscopes, bronchoscopes

Cystoscopy – is a procedure that allows doctors to examine the lining of the bladder and the tube that carries urine out of the body

Bladder Cancer

Most Expensive Cancer to Treat



- \$4B bladder cancer surveillance
- > 600,000 living in fear of recurrence
- > 50% recurrence rate in non-muscle
- 81,190 new cases/year; 17,240 deaths*


Bladder cancer
is the 6th most
common cancer
in the U.S.

Current Standard of Care – White Light

Significant Unmet Medical Need Remains


- Current procedures performed with white light (visible light) the gold standard for decades
- > 90% of the market

White Light



- Highly effective for visualizing cancerous tumors that protrude above the bladder wall


Limitations of White Light



- Flat tumors may look the same as normal tissue
- Not effective in visualizing the margins (edges) of the tumor

Emerging Standard of Care – Blue Light

Contrast Agents Are Used With White Light and a Blue Filter, Inducing Fluorescence




Benefits:

- Blue light excites fluorescence in the tumor, highlighting the cancerous tissue
- Easier to detect flat cancers and visualize margins
- Blue light added to American Urology Association Guidelines



Competitive Systems

Must “Toggle” Between White & Blue Imaging Modes

White Light
Image



Fluorescence
with Blue Light




White light image shows the full landscape of the bladder but does not highlight cancer.

Blue light highlighting the cancerous tissue in the bladder.


Barriers to Adoption:

- Surgeon cannot operate using the blue light image
- Blue image not in real-time, may lose orientation in bladder
- Surgeon must manually “switch” between two different images
- Fluorescing agent available with only one scope manufacturer



New Standard of Care – i/Blue Imaging System

Imagin Makes Cystoscopy With Blue Light Practical



i/Blue Imaging System Benefits:

- Simultaneous acquisition of differing images
 - No toggling back and forth
 - Displays white and blue images simultaneously on one monitor
 - Shows cancer in context
 - Enables surgeon to better visualize and resect the cancer
- Adapts seamlessly to most types of endoscopes on the market
- Potentially “sees” the cancer more rapidly
- May expand to physician’s office

i/Blue Imaging System

First Functional Units





On-going Development

Disruptive Technology: Multiple Markets

- Focused on expansion into multiple endoscopic procedures
- Abdominal surgery, colorectal, and lung
- With appropriate changes i/Blue can accommodate the most commonly used fluorescing contrast agents, such as Indocyanine green (ICG)
- Initial prototype built, animal bile duct evaluation – data presented



PROCEEDINGS PAPER:
Enhanced visualization of the bile duct via parallel white light and indocyanine green fluorescence laparoscopic imaging
[Stavros G. Demos](#) ; [Shiro Urayama](#)
[\[+\] Author Affiliations](#)
Proc. SPIE 8940, Optical Biopsy XII, 89400R (March 17, 2014);
doi:10.1117/12.2044271

- Combines multiple illumination sources into one system

*Imagin Medical, Inc. is a development stage company and does not currently have any Medical Device Regulatory Approvals or Clearances to market products in any jurisdiction

Market Opportunity

Well Protected

Issued

- U.S. Patent 7,149,567 - *Near-Infrared Spectroscopic Tissue Imaging for Medical Applications*
- U.S. Patent 7,257,437 - *Autofluorescence Detection and Imaging of Bladder Cancer Realized Through a Cystoscope*
- U.S. Patent 8,285,015 - *Simultaneous Acquisition of Differing Image Types*

Pending

- U.S. Patent Application No. 13/601,918 - *Simultaneous Acquisition of Differing Image Types*
- Additional IP being filed



Regulatory Overview

Q-Submission completed

- Study planned to compare i/Blue Imaging System performance to other imaging devices currently on the market
- Device will be used with FDA-approved imaging agents and routes of administration
- Expect 12-month process, but could be longer depending on chosen claims, (e.g., comparable vs. superior)
- Full GMP Compliant Quality Management System (QMS) required
- King & Spalding, LLP, Washington DC, will manage all government regulatory approvals

Growth Strategy


Market Entry and Expansion

- Start with bladder cancer surgery and then expand to bladder cancer Fluorescence Imaging biopsy
- Create immediate credibility in the market:
 - Develop physician champions/establish 4 *Centers of Excellence*
- Drive to profitability using 7–10 independent sales reps
- Expand market to include additional medical procedures:


General




Gynecology



Colorectal



Thoracic



Experienced Management Team

Strong Track Record of Success

	Experience	Years
Jim Hutchens President and CEO	Origin Partners, Microvasive Endoscopy - Boston Scientific, Microsurge, Choice Therapeutics	30
John Vacha CFO	Intact Medical, Deloitte & Touche	21
Michael Vergano Director of Operations	The Harvest Group, Apple Medical, Ciba Corning Diagnostics, Microsurge, Boston Scientific	30
Jay Eastman Director Development	Optel, Inc., University of Rochester, Laboratory of Laser Energetics, Lucid, Inc.	28
Pam Papineau Director of Regulatory Affairs	Baxter, Boston Scientific, Cogentix (Vision-Sciences)	30



Strong M&A Environment

If You Can't Beat Them, Buy Them



PINPOINT

- Introduced Q4, 2007
- White light + ICG fluorescence endoscopic system
- Visualization of blood flow and tissue perfusion during surgery
- Ability to **overlay/combine** white light and fluorescence imaging in real time



System 1588

- Introduced Q1, 2016
- White light + ICG fluorescence endoscopic system
- Visualization of blood flow and tissue perfusion during surgery
- Surgeons need to **toggle** back and fourth between white light and fluorescence image



June 2017: “Stryker Corp. to acquire Novadaq Technologies for \$701 million”

Financial Highlights

- Liquidity and share capital
CSE: IME; OTCQB: IMEXF
- Strong cash position

Current Share Structure

Share Class (as of 12/31/2018)	# of Shares
Common Shares	177,340,278
Warrants Outstanding*	58,372,730
Options Outstanding	11,600,000
Fully Diluted Shares Outstanding	247,313,008

Insider Ownership

Shares Held by Insiders	9,561,857
Insider Ownership	5.39%

US \$ Equivalents

*April 2020: 20,283,597 @ \$0.30 = \$6.1M

Jan 2022: 39,335,800 @ \$0.11 = \$4.3M



Key Investment Risks Removed, High Investment Return

1

Disruptive Imaging Technology

- Significant unmet medical need
- Potential to dramatically reduce bladder cancer recurrence rates
- Addressing \$750M+ global market

2

Mitigated R&D Risk

- Concept is already proven
- Pilot production underway
- This is an execution play

3

Management Team

- Experienced medical device management team
- Strong individual track records of success

4

Strong M&A Market

- Most large medical device companies grow by acquisition, not organically
- Company expects to have significant value and multiple liquidity options

Thank You!

Contact Information:

Jim Hutchens

President & CEO

(617) 571-6006

jhutchens@imaginmedical.com